Literature DB >> 6783063

Factor VIII:C and VIII:CAg response in patients with haemophilia A and von Willebrand's disease after administration of different factor VIII concentrates or plasma.

L Holmberg, L Borge, I M Nilsson.   

Abstract

Factor VIII procoagulant activity (VIII:C) and factor VIII procoagulant antigen (VIII:CAg) were studied in seven patients with haemophilia A after administration of three different factor VIII concentrates or plasma. The in vivo recovery of VIII:CAg was less than that of VIII:C and the disappearance rate of VIII:CAg was much higher either when concentrates or plasma were given. The half-life of VIII:C was thus about 12 h but of VIII:CAg only about 3 h or less. Six patients with von Willebrand's disease were studied after administration of AHF-Kabi. In contrast to haemophilia A the discrepancy between VIII:C and VIII:CAg disappearance rates was not present in von Willebrand's disease, since both VIII:C and VIII:CAg showed a typical progressive increase. We conclude that factor VIII:C given to haemophilia patients does not behave like native VIII:C, not even when fresh plasma is used. Patients with von Willebrand's disease are capable of forming a normal VIII:C when appropriately stimulated.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6783063     DOI: 10.1111/j.1365-2141.1981.tb02688.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  2 in total

1.  The use of heat-treated Factor VIII-concentrates in von Willebrand's disease.

Authors:  M Köhler; P Hellstern; E Wenzel
Journal:  Blut       Date:  1985-01

Review 2.  Clinical pharmacokinetics of factor VIII in patients with classic haemophilia.

Authors:  A Messori; G Longo; M Matucci; M Morfini; P L Ferrini
Journal:  Clin Pharmacokinet       Date:  1987-12       Impact factor: 6.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.